Aerobic Exercise Training in Mild Cognitive Impairment Study (AETMCI)

February 5, 2020 updated by: Rong Zhang, University of Texas Southwestern Medical Center

Mild Cognitive Impairment:Cerebrovascular Dysfunction and Exercise

This study is being done to find out whether regulation of brain blood flow is altered in patents with mild cognitive impairment (those who have memory problems but otherwise healthy) when compared with healthy elderly individuals. In addition, this study will determine whether exercise training improves brain blood flow, brain structure, and brain function in patients with mild cognitive impairment (MCI).

This is a research study because at present the investigators know little about brain blood flow regulation in patients with mild cognitive impairment. The investigators also know little about whether exercise training improves brain blood flow, brain structure, and brain function in patients with mild cognitive impairment.

Study Overview

Status

Completed

Detailed Description

We plan to study 70 patients with amnestic MCI and 30 healthy older adults with similar age, sex, and educational level in this research at the University of Texas Southwestern(UTSW) Medical Center Dallas and Texas Health Presbyterian Hospital Dallas - Institute for Exercise an Environmental Medicine (IEEM).

To help decide if you qualify to be in this study, the researchers may ask you questions about your health, including medications you take and any surgical procedures you have had. You may also have to fill out certain forms or have the following exams, tests or procedures. The screening process usually takes 2-3 hours.

You will be required to come for 7-9 visits including the initial screening for eligibility to participate in this study. The experiments will measure your brain perfusion, vascular function and exercise capacity.

For the healthy controls, the expected length of this study will be about 2-3 months including all the test visits. Your participation in this study will end following completion of your testing.

For those with Mild Cognitive Impairment, the expected length of this study will be about 18 months including all the test visits and exercise training. Your participation in this study will end following completion of your repeat testing after one-year exercise training or control intervention. On occasion, training may be delayed due to injury, illness or personal matters. If this is the case, your enrollment in the study may last longer than one year as we attempt to complete the training and testing.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Dallas, Texas, United States, 75231
        • UT Southwestern ADC/Institute for Exercise and Environmental Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 55-80 years old, Male or Female
  2. Control Subjects: absence of cognitive complaints and normal performance in Uniform Data Set (UDS) neuropsychological tests.
  3. For patients: Diagnosis of amnestic MCI (single and multiple domains) by Petersen's criteria (as modified for ADNI-GO study).
  4. Stable medical condition for > 6 months
  5. Sable medications for >2 months (use of cholinesterase inhibitors, or prior use of multivitamins is allowed)
  6. Caregiver/informant available to accompany patient for scheduled visits in case the patient develops cognitive impairment that interferes with independent study participation.
  7. Fluency of patient and caregiver in English
  8. Ability to return to clinic for additional visits over a 12 month period.
  9. ≥ 10 years of education or enough work history to exclude mental retardation.
  10. Adequate visual and auditory acuity to allow neuropsychological testing.
  11. Screening laboratory tests and ECG without significant abnormalities that might interfere with the study.
  12. Physical ability to undergo endurance exercise training.

Exclusion Criteria:

  1. Diagnosis of Alzheimer's Disease or other type of dementia.
  2. Participant enrolled in any other investigational drug study within 2 months or longer, depending on the investigational drug half-life.
  3. Modified Hachinski Score ≥ 4.
  4. Subject has history in the past 2 years of epileptic seizures, or DSM-IV criteria of any major psychiatric disorders.
  5. Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, mental retardation or serious neurological disorder.
  6. Carotid stent or sever stenosis.
  7. Significant history of active alcoholism or drug abuse.
  8. History of myocardial infarction within the previous year. Unstable cardiac, renal, lung, liver or other severe chronic diseases.
  9. Uncontrolled hypertension (Systolic Blood Pressure (SBP) ≥160, Diastolic Blood Pressure (DBP) ≥100)or hypotension (SBP <100 mmHg).
  10. Currently diagnosed and being treated for Diabetes Mellitus (DM).
  11. Obesity with Body Mass Index (BMI) ≥ 35.
  12. History of familial early onset (<55 years old) dementia
  13. Pacemaker or other medical device of metal that precludes performing MRI.
  14. Subjects who have been engaged in moderate intensity aerobic exercise training for > 30 minutes, 3 times per week over the past 2 years.
  15. History of a clinical diagnosis of B12 deficiency or hypothyroidism. (stable treatment for at least 3 months is allowed).
  16. Chronic inflammatory diseases including, lupus, rheumatoid arthritis and polymyalgia rheumatica.

Prohibited Medications:

  • narcotics
  • anti-Parkinsonian medications
  • anti-convulsants for treatment of seizure disorder
  • drugs that can influence psychometric test results.

    • Subjects on a statins or non-steroidal anti-inflammatory drug (NSAID) are eligible but must be on a stable dose for at least 2 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group
A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
Experimental: Exercise
Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive function
Time Frame: One year
A comprehensive battery of neuropsychological tests focused on memory and executive function will be used to assess effects of exercise on cognitive function.
One year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cerebrovascular function
Time Frame: One year
Transcranial Doppler and perfusion magnetic resonance imaging (MRI) will be used to measure cerebrovascular function/brain perfusion before and after exercise training.
One year
Brain tissue volume and white matter integrity
Time Frame: One year
Magnetic resonance imaging (MRI) will be used to measure changes in brain volume and white matter integrity before and after exercise training.
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rong Zhang, PhD, UTSW

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2010

Primary Completion (Actual)

September 1, 2016

Study Completion (Actual)

September 1, 2016

Study Registration Dates

First Submitted

June 16, 2010

First Submitted That Met QC Criteria

June 16, 2010

First Posted (Estimate)

June 17, 2010

Study Record Updates

Last Update Posted (Actual)

February 7, 2020

Last Update Submitted That Met QC Criteria

February 5, 2020

Last Verified

October 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • 032009-065
  • R01AG033106-01A2 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment

Clinical Trials on Exercise

3
Subscribe